PD04.04. Prognostic Significance of B7-H3 Expression in High-Risk Locally Advanced ESCC After Trimodality Therapy and Adjuvant Pembrolizumab: Post-Hoc Analysis
Clicks: 1
ID: 325656
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #37 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Topic Esophageal Cancer: Molecular Biology/Pathology Background B7-H3 (CD276) is an immunoregulatory molecule and emerging therapeutic target. The prognostic value of B7-H3 expression in locally advanced esophageal squamous cell carcinoma (ESCC) treated with multimodality therapy plus adjuvant pembrolizumab was unclear. We performed a post-hoc analysis of a single-arm phase II ESCC patient cohort (NCT03322267) treated with protocol-specified adjuvant cisplatin-based chemoradiotherapy (CRT) followed by pembrolizumab for post-neoadjuvant CRT esophagectomy, pathology revealing risk factors for recurrence including involved or close margins (≤1 mm), extranodal extension of involved lymph nodes, and ypN2-3 stage. Methods Patients in the study cohort with adequate surgical tissue for B7-H3 immunohistochemistry (IHC) were included. B7-H3 (clone EPR20115, Abcam) was scored by H-score. H-score values of B7-H3 IHC analyses calculated by multiplying the percentage of cells positive by 1, 2 or 3 based on expression intensity. PD-L1 combined positive score (CPS) was assessed with Dako 22C3. Relapse-free survival (RFS) and overall survival (OS) were analyzed. Cox proportional hazards models adjusted for age, performance status, post-neoadjuvant therapy pathology stage, margin status, lymphovascular invasion, perineural invasion, tumor regression grade, and PD-L1 expression. Results Twenty-four patients were evaluable (B7-H3 H-score ≥150: n=7; <150: n=17). PD-L1 CPS was similar between the B7-H3 H-score ≥150 vs <150 groups (median 5.0 vs 4.0; p=0.637). B7-H3 H-score ≥150 was associated with shorter RFS (median 4.6 vs 18.0 months; p =0.002) and OS (median 10.2 vs 19.8 months; p =0.041). In multivariable Cox model, B7-H3 H-score ≥150 independently predicted inferior RFS (p =0.039) but not OS (p =0.108). PD-L1 CPS ≥10 was not significant for RFS (p =0.253) or OS (p =0.428). Conclusion High tumor B7-H3 (H-score ≥150) identified a higher-risk subgroup with shorter RFS after multimodality therapy plus adjuvant pembrolizumab, independent of PD-L1 CPS and adverse pathologic features, supporting B7-H3 expression for risk stratification and warranting external validation.
| Reference Key |
openalex_W7203945226
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Chien-Huai Chuang, Jhe‐Cyuan Guo, Ta‐Chen Huang, Yen-Lin Huang, Hung‐Yang Kuo, Chia-Chi Lin, Tsung‐Che Wu, Pei‐Ming Huang, Jang‐Ming Lee, Chih‐Hung Hsu |
| Journal | diseases of the esophagus : official journal of the international society for diseases of the esophagus |
| Year | 2026 |
| DOI |
10.1093/dote/doag077.099
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.